CN1961001B - 参与病毒蛋白的免疫抑制作用的调节的多肽序列 - Google Patents

参与病毒蛋白的免疫抑制作用的调节的多肽序列 Download PDF

Info

Publication number
CN1961001B
CN1961001B CN2005800161375A CN200580016137A CN1961001B CN 1961001 B CN1961001 B CN 1961001B CN 2005800161375 A CN2005800161375 A CN 2005800161375A CN 200580016137 A CN200580016137 A CN 200580016137A CN 1961001 B CN1961001 B CN 1961001B
Authority
CN
China
Prior art keywords
seq
protein
env
immunosuppressive
mutated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800161375A
Other languages
English (en)
Chinese (zh)
Other versions
CN1961001A (zh
Inventor
M·勒纳尔
M·曼吉尼
T·海德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guo Jiakeyanzhongxin
Gustavus Institute
Thackeray Paris, University of
Original Assignee
Gustavus Institute
Universite Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gustavus Institute, Universite Paris Sud filed Critical Gustavus Institute
Publication of CN1961001A publication Critical patent/CN1961001A/zh
Application granted granted Critical
Publication of CN1961001B publication Critical patent/CN1961001B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2005800161375A 2004-03-30 2005-03-30 参与病毒蛋白的免疫抑制作用的调节的多肽序列 Expired - Fee Related CN1961001B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30
EP04290838.4 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (2)

Publication Number Publication Date
CN1961001A CN1961001A (zh) 2007-05-09
CN1961001B true CN1961001B (zh) 2012-09-05

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800161375A Expired - Fee Related CN1961001B (zh) 2004-03-30 2005-03-30 参与病毒蛋白的免疫抑制作用的调节的多肽序列

Country Status (14)

Country Link
US (2) US8178657B2 (enExample)
EP (1) EP1732585B1 (enExample)
JP (1) JP5060284B2 (enExample)
CN (1) CN1961001B (enExample)
AT (1) ATE472334T1 (enExample)
AU (1) AU2005229411B2 (enExample)
BR (1) BRPI0509497B1 (enExample)
CA (1) CA2561376C (enExample)
DE (1) DE602005022056D1 (enExample)
ES (1) ES2347445T3 (enExample)
IL (1) IL178205A (enExample)
MX (1) MXPA06011272A (enExample)
WO (1) WO2005095442A1 (enExample)
ZA (1) ZA200608178B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103957932A (zh) * 2011-07-20 2014-07-30 梅里亚有限公司 包含最优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
WO2006103562A2 (en) 2005-03-30 2006-10-05 Centre National De La Recherche Scientifique (Cnrs) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
CA2749183C (en) 2009-01-09 2017-11-28 Marc Sitbon New receptor binding ligands, their use in the detection of cells with biological interest
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
US20130260394A1 (en) * 2010-09-17 2013-10-03 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
AU2012350258B2 (en) * 2011-12-07 2017-03-02 Centre National De La Recherche Scientifique Mutated lentiviral ENV proteins and their use as drugs
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
US9974852B2 (en) 2013-06-07 2018-05-22 Viroxis Sas Mutated non-primate lentiviral Env proteins and their use as drugs
EP3309178A4 (en) * 2015-06-11 2019-05-08 Keio University FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR
CA2999792A1 (en) * 2015-10-01 2017-04-06 Magdalena Janina LASKA Use of human derived immunosuppressive proteins and peptides as medicaments
JP7277466B2 (ja) 2017-09-01 2023-05-19 インプラザー エー・ペー・エス 疾患の予防および／または治療における使用のためのワクチン
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク． Ａｒｃベースのカプシドおよびその使用
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
CA3204201A1 (en) 2021-01-13 2022-07-21 Thierry Heidmann Measles-hiv or measles-htlv vaccine
AU2024256799A1 (en) 2023-04-21 2025-11-06 Inprother Aps Improved expression of surface-displayed antigens

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0377842A1 (en) * 1988-12-13 1990-07-18 President And Fellows Of Harvard College Prototype FeLV isolates for use in disease models and vaccines
CN1281371A (zh) * 1997-11-17 2001-01-24 茜泊坎普公司 获得用于预防与逆转录病毒感染有关的致病作用的疫苗的方法
WO2002047720A2 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
EP1224291A1 (en) * 1999-10-28 2002-07-24 Universite De Geneve Multiple sclerosis-related superantigen
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0377842A1 (en) * 1988-12-13 1990-07-18 President And Fellows Of Harvard College Prototype FeLV isolates for use in disease models and vaccines
CN1281371A (zh) * 1997-11-17 2001-01-24 茜泊坎普公司 获得用于预防与逆转录病毒感染有关的致病作用的疫苗的方法
WO2002047720A2 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Arille R. Rosenberg et. al.Early assembly step of a retroviral envelope glycoprotein:analysis using a dominant negative assay.The Journal of Cell Biology145 1.1999,145(1),57-68.
Arille R. Rosenberg et. al.Early assembly step of a retroviral envelope glycoprotein:analysis using a dominant negative assay.The Journal of Cell Biology145 1.1999,145(1),57-68. *
Laurence Benit et.al.Identifiction,phylogeny, and evolution of Retroviral ElementsBased on Their Envelope Genes.Journal of Virology75 23.2001,75(23),11709-11719.
Laurence Benit et.al.Identifiction,phylogeny, and evolution of Retroviral ElementsBased on Their Envelope Genes.Journal of Virology75 23.2001,75(23),11709-11719. *
Lelia Delamarre et.al.A novel human T-leukemia virus type 1 cell-to-celltransmission assay permits definition of SU glycoprotein aminoacids important for infectivity.Journal of Virology71 1.1997,71(1),259-266.
Lelia Delamarre et.al.A novel human T-leukemia virus type 1 cell-to-celltransmission assay permits definition of SU glycoprotein aminoacids important for infectivity.Journal of Virology71 1.1997,71(1),259-266. *
Marianne Mangeney et. al.Tumor cells expressing a retroviral envelope escape inmmunrejection in vivo.Proceedings of the National Academy of Sciences of the United States of America95 25.1998,95(25),14920-14925.
Marianne Mangeney et. al.Tumor cells expressing a retroviral envelope escape inmmunrejection in vivo.Proceedings of the National Academy of Sciences of the United States of America95 25.1998,95(25),14920-14925. *
Sandra Blaise et.al.Identification of an envelope protein from the FRD family ofhuman endogeous retroviruses (HERV-FRD) conferringinfectivity and functional conservation among simians.Journal of Viology78 2.2004,78(2),1050-1054.
Sandra Blaise et.al.Identification of an envelope protein from the FRD family ofhuman endogeous retroviruses (HERV-FRD) conferringinfectivity and functional conservation among simians.Journal of Viology78 2.2004,78(2),1050-1054. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103957932A (zh) * 2011-07-20 2014-07-30 梅里亚有限公司 包含最优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗
CN103957932B (zh) * 2011-07-20 2017-06-23 梅里亚有限公司 包含最优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗

Also Published As

Publication number Publication date
BRPI0509497B1 (pt) 2022-07-19
MXPA06011272A (es) 2007-04-17
WO2005095442A8 (en) 2006-11-02
CN1961001A (zh) 2007-05-09
AU2005229411A1 (en) 2005-10-13
AU2005229411B2 (en) 2010-11-18
US8178657B2 (en) 2012-05-15
US20080008683A1 (en) 2008-01-10
DE602005022056D1 (de) 2010-08-12
JP2008506357A (ja) 2008-03-06
US8597657B2 (en) 2013-12-03
BRPI0509497A (pt) 2007-09-11
IL178205A (en) 2015-05-31
US20120189647A1 (en) 2012-07-26
EP1732585B1 (en) 2010-06-30
CA2561376A1 (en) 2005-10-13
IL178205A0 (en) 2006-12-31
ES2347445T3 (es) 2010-10-29
WO2005095442A1 (en) 2005-10-13
JP5060284B2 (ja) 2012-10-31
EP1732585A1 (en) 2006-12-20
ATE472334T1 (de) 2010-07-15
ZA200608178B (en) 2008-10-29
CA2561376C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
CN1961001B (zh) 参与病毒蛋白的免疫抑制作用的调节的多肽序列
US10335482B2 (en) Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
ES2380228T3 (es) Retrovirus endógeno y proteínas codificadas por env como diana para el tratamiento del cancer
WO2008099284A2 (en) Hiv combination vaccine and prime boost method
US20150037371A1 (en) Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
JP6612237B2 (ja) ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター
JP4926060B2 (ja) 免疫をモデュレーションするための突然変異したＨＩＶＮｅｆ
EP1047791A1 (fr) Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
WO2011092199A1 (en) Mutated xmrv env proteins in the immunosuppressive domain
US20220184202A1 (en) A recombinant htlv-1 vaccine
CN104169295B (zh) 突变的慢病毒env蛋白及其用作药物的用途
Wan et al. Engineered protein destabilization reverses intrinsic immune evasion for candidate vaccine pan-strain KSHV and SARS-CoV-2 antigens
KR20230112691A (ko) 바이러스 감염을 치료하기 위한 방법 및 조성물
EP1373537A2 (en) Viral vectors
EP3104884B1 (en) A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection
Yuen et al. Changes in the N-and C-terminal sequences of the murine R7 Gag-tMos protein affect brain lesion induction
AU2002249393A1 (en) Viral vectors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20211231

Address after: Villejuif, France

Patentee after: Gustavus Institute

Patentee after: Guo Jiakeyanzhongxin

Patentee after: University of Thackeray, Paris

Address before: Villejuif, France

Patentee before: Gustavus Institute

Patentee before: Guo Jiakeyanzhongxin

Patentee before: UNIVERSITE PARIS-SUD 11

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120905